As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 188 188 |
41%
41%
|
|
| Gross Profit | 175 175 |
42%
42%
|
|
| EBITDA | 19 19 |
54%
54%
|
|
| EBIT (Operating Income) EBIT | -14 -14 |
288%
288%
|
|
| Net Profit | -76 -76 |
281%
281%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Todd Davis |
| Employees | 68 |
| Founded | 1987 |
| Website | www.ligand.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


